Compounds for the treatment of alzheimer's disease
AssigneeBonnie Davis
InventorsBonnie M. Davis, Madeleine M. Joullie
Life of this patent
Estimating the term…
Abstract
The present invention is directed to analogs of galanthamine of the structure 1 and their use in treating Alzehimer's diseases and related dementias.
Claims40
A method of treating Alzheimer's disease and related dementias which comprises administering to a patient suffering from such a disease a therapeutically effective amount of a compound of the Formula I
- 51
- wherein the broken line represents an optionally present double bond in one or two of the positions shown, R1 and R2 are each selected independently from the group consisting of hydrogen, hydroxyl, amino, phenylamino or alkylamino, cyano, sulfhydryl, alkoxy of 1-6 carbon atoms, alkylthio, aryloxy, aralkoxy, C1-6 alkyl carbonate or R5-substituted phenyl or benzyl carbonate, R5-substituted aryloxy, R5-substituted arylthio, aralkoxy t an aliphatic or aryl carbamyl group wherein the aliphatic or aryl moiety may be R5 substituted or unsubstituted, aralkylthio, R5-substituted aryloxymethyl, alkanoyloxy, hydroxy-substituted alkanoyloxy, benzoyloxy, aryloxy carbonyl, R1 may also be alkyl of up to 14 carbon atoms, or hydroxy methyl, R2 may also be carboxymethyl provided that at least one of R1 and R2 is hydroxy, amino or alkylamino unless R7 or R8 is hydroxymethyl,
- R3 is hydrogen, straight or branched chain alkyl of 1-6 carbon atoms, cycloalkyl methyl, phenyl, R5 substituted phenyl, alkylphenyl, R5 alkylphenyl, heterocyclic selected from α- or β-furyl, α- or β-thienyl or thenyl, pyridyl, pyrazinyl and pyrimidyl, alkyl heterocyclic or R′-substituted heterocyclyl, where R′ is alkyl or alkoxy and heterocyclyl is selected from α- or
- β-furyl, thienyl, thenyl, pyridyl, pyrazinyl, pyrimidyl or is methylpyrryl or
- R3 is alkanoyl of 1 to 8 carbon atoms or aroyl wherein the aryl group is of 6 to 10 carbon atoms, the alkyl and aryl portions of said groups optionally being substituted by R5 groups as hereinafter defined or
- R3 is the residue of a compound having adrenergic or monoamino oxidase activity and said residue being selected from the group consisting of
- 52
- wherein Hal is a halogen, p is 0, 1 or 2, q is 0 or 1, r is 0 or 1 and Z is selected from the group consisting of
- 53
- wherein Q is hydrogen or hydroxy, L is hydrogen or C1-4 alkyl, G is hydrogen, C1-4 alkyl, alkylphenyl wherein said phenyl group is optionally substituted by hydroxy or methylene deoxy, or is alkylamino
- 54
- wherein G is as defined above,
- 55
- c) CH2CH2NH—NH2 and
- 56
- each R4 is independently selected from hydrogen, hydroxyl, sulfhydryl, alkyl, aryl, alkoxy, mercaptoalkyl, aryloxy, mercaptoaryl, alkarloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro, chloro, bromo iodo and trifluoromethyl, R5 is selected from the group consisting of hydroxyl, sulfhydryl, alkyl, aryl, alkoxy, mercaptoalkyl, aryloxy, mercaptoaryl, alkaryloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, fluoro, chloro, bromo, iodo and trifluoromethyl,
- R6 is hydrogen, halo, trifluoromethyl or alkyl of 1 to 4 carbon atoms,
- R7 is selected from the same groups as R4 or may be hydroxy alkyl of 1-2 carbon atoms,
- R8 is hydrogen or hydroxymethyl,
- R9 is hydrogen or alkyl of 1 to 6 carbon atoms, or when R2 is hydroxyl R9 may be
- 57
- or
- R2 and R9 may jointly form a keto group provided that R1 is hydroxy or amino,
- X is oxygen or NH
- Y is nitrogen
- with the proviso that when X is O, R3 is not methyl when R1 is methoxy, R2 is hydroxy, all R4's are hydrogen or a pharmaceutically acceptable acid addition salt thereof.
A compound of the formula
- 66
- wherein the broken line represents an optionally present double bond in one of the two positions shown, R1 and R2 are each selected independently from the group consisting of hydrogen, hydroxyl, amino or alkylamino, cyano, sulfhydryl, alkoxy preferably of 1-6 carbon atoms, alkylthio, aryloxy, arylthio, R5-substituted aryloxy, R5-substituted arylthio, aralkoxy, an aliphatic or aryl carbamyl group wherein the aliphatic or aryl moiety may be R5 substituted or unsubstituted, aralkylthio, R5-substituted aralkoxy, R5-substituted aralkylthio, aryloxymethyl, R5 substituted aryloxymethyl, alkanoyloxy, hydroxy-substituted alkanoyloxy, benzoyloxy, R5-substituted benzoyloxy, aryloxy carbonyl and R5-substituted aryloxy carbonyl, R1 may also by alkyl of up to 14 carbon atoms, or hydroxy methyl, R2 may also be keto;
- R2 may also be carboxymethyl provided that at least one of R1 and R2 is hydroxy amino or alkylamino unless R7 or R8 is hydroxymethyl,
- R3 is hydrogen, straight or branched chain alkyl, preferably of 1-6 carbon atoms, cycloalkyl methyl, alkylphenyl, R5-substituted alkylphenyl, heterocyclic selected from the group consisting of α- or β-furyl, α- or β-thienyl or thenyl, pyridyl, pyrazinyl or pyrimidyl groups or
- R3 is an alkyl or alkoxy substituted derivative of said heterocyclic groups or
- R3 is alkanoyl of 1 to 8 carbon atoms or aroyl wherein the aryl group is of 6 to 10 carbon atoms, the alkyl and aryl portions of said groups optionally being substituted by R5 groups as hereinafter defined or
- R3 is the residue of a compound having adrenergic or monoamino oxidase activity and is selected from the group consisting of
- 67
- wherein Hal is a halogen, preferably chloro, p is 0, 1 or 2, q is 0 or 1, r is 0 or 1 and Z is selected from the group consisting of
- 68
- wherein Q is hydrogen or hydroxy, L is hydrogen or C1-4 alkyl, G is hydrogen, C1-4 alkyl, alkylphenyl wherein said phenyl group is optionally substituted by hydroxy or methylene deoxy, or is alkyl alkanylamino
- 69
- wherein G is as defined above,
- 70
- c) —CH2—CH2NH—NH2 and
- 71
- each R4 is independently selected from hydrogen, hydroxyl, sulfhydryl, alkyl, aryl, aralkyl, alkoxy, mercaptoalkyl, aryloxy, mercaptoaryl, alkaryloxy, mercaptoalkylaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro, chloro, bromo, iodo, and trifluoromethyl, and R5 is selected from the groups consisting of hydroxyl, sulfhydryl, alkyl, aryl, alkoxy, mercaptoalkyl, aryloxy, mercaptoaryl, alkaryloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro, chloro, bromo, iodo and trifluoromethyl,
- R6 is hydrogen, halo, trifluoromethyl or alkyl of 1 to 4 carbon atoms,
- R7 is selected from the same groups as R4 or may be hydroxy or mercapto alkyl of 1-2 carbon atoms,
- R8 is hydrogen or hydroxymethyl,
- R9 is hydrogen or alkyl of 1 to 6 carbon atoms, or when R2 is hydroxyl R9 may be
- 72
- R2 and R9 may jointly form a semi carbazone, oxime, phenyl hydrazone or keto group,
- and pharmaceutically-acceptable acid addition salts thereof with the provisoes that 1) is not methyl when R1 is methoxy, R2 is hydroxy, and all R4's are hydrogen, 2) that when the 3-4 bond is saturated that R1 is not hydrogen when R2 is methoxy or hydrogen, R4 is hydrogen, R3 is methyl and R7 is hydrogen or ethoxy, 3) R1 is not acetoxy when R2 is hydroxy, R3 is methyl, R4 is hydrogen and R7 is hydrogen, 4) when R2 is hydroxy, R3 is not hydrogen or benzyl when R1 is methoxy and all of R4 and R7 are hydrogen, and 5) that the compound is not leucotamine, O-methyl leucotamine, O-methyl leucotamine acetate, sanguinine, lycoramine, O-demethyl lycoramine, childanthine, habranthine, N-formyl galanthamine, acetyl dihydrogalanthamine or N,O-diacetyl N-demethyl galanthamine, deoxydemethyl lycoramine, dihydrochildanthine, sanguinine, dihydrosanguinine lycoramine acetate, deoxylycoramine or deoxydemethyl, lycoramine carbamate.
A compound according to claim 29 wherein R1 is hydroxy, alkoxy of 1-6 carbon atoms or alkanoyloxy of 1-6 carbon atoms, R2 is CONHR wherein R is as defined in claim 32, R3 is hydrogen, lower alkyl or cyclopropyl substituted lower alkyl and each of R4, R6, R7, R8 and R9 are hydrogen.
A pharmaceutical composition for treatment of Alzheimer's disease and related dementias comprising a compound of the formula
- 73
- wherein the broken line represents an optionally present double bond in one or two of the positions shown, R1 and R2 are each selected independently from the group consisting of hydrogen, hydroxyl, amino, phenylamino or alkylamino, cyano, sulfhydryl, alkoxy of 1-6 carbon atoms, alkylthio, aryloxy, aralkoxy, C1-6 alkyl carbonate or R5-substituted phenyl or benzyl carbonate, R5-substituted aryloxy, R5-substituted arylthio, aralkoxy, an aliphatic or aryl carbamyl group wherein the aliphatic or aryl moiety may be R5 substituted or unsubstituted, aralkylthio, R5-substituted aryloxymethyl, alkanoyloxy, hydroxy-substituted alkanoyloxy, benzoyloxy, aryloxy carbonyl, R1 may also be alkyl of up to 14 carbon atoms, or hydroxy methyl, R2 may also be carboxymethyl provided that at least one of R1 and R2 is hydroxy, amino or alkylamino unless R7 or R8 is hydroxymethyl,
- R3 is hydrogen, straight or branched chain alkyl of 1-6 carbon atoms, cycloalkyl methyl, phenyl, R5 substituted phenyl, alkylphenyl, R5 alkylphenyl, heterocyclic selected from α- or β-furyl, α- or β-thienyl or thenyl, pyridyl, pyrazinyl and pyrimidyl, alkyl heterocyclic or R′-substituted heterocyclyl, where R′ is alkyl or alkoxy and heterocyclyl is selected from α- or
- β-furyl, thienyl, thenyl, pyridyl, pyrazinyl, pyrimidyl or is methylpyrryl or
- R3 is alkanoyl of 1 to 8 carbon atoms or aroyl wherein the aryl group is of 6 to 10 carbon atoms, the alkyl and aryl portions of said groups optionally being substituted by R5 groups as hereinafter defined or
- R3 is the residue of a compound having adrenergic or monoamino oxidase activity and said residue being selected from the group consisting of
- 74
- wherein Hal is a halogen, p is 0, 1 or 2, q is 0 or 1, r is 0 or 1 and Z is selected from the group consisting of
- 75
- wherein Q is hydrogen or hydroxy, L is hydrogen or C1-4 alkyl, G is hydrogen, C1-4 alkyl, alkylphenyl wherein said phenyl group is optionally substituted by hydroxy or methylene deoxy, or is alkylamino
- 76
- wherein G is as defined above,
- 77
- c) CH2CH2NH—NH2 and
- 78
- each R4 is independently selected from hydrogen, hydroxyl, sulfhydryl, alkyl, aryl, alkoxy, mercaptoalkyl, aryloxy, mercaptoaryl, alkarloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkarylamino, fluoro, chloro, bromo iodo and trifluoromethyl, R5 is selected from the group consisting of hydroxyl, sulfhydryl, alkyl, aryl, alkoxy, mercaptoalkyl, aryloxy, mercaptoaryl, alkaryloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, fluoro, chloro, bromo, iodo and trifluoromethyl,
- R6 is hydrogen, halo, trifluoromethyl or alkyl of 1 to 4 carbon atoms,
- R7 is selected from the same groups as R4 or may be hydroxy alkyl of 1-2 carbon atoms,
- R8 is hydrogen or hydroxymethyl,
- R9 is hydrogen or alkyl of 1 to 6 carbon atoms, or when R2 is hydroxyl R9 may be
- 79
- or
- R2 and R9 may jointly form a keto group provided that R1 is hydroxy or amino,
- X is oxygen or NH
- Y is nitrogen
- with the proviso that when X is O, R3 is not methyl when R1 is methoxy, R2 is hydroxy, all R4's are hydrogen and a pharmaceutically acceptable solvent diluent or carrier.
A method of treating Alzheimer's disease and related dementias comprising administering to a patient suffering from such a disease a therapeutically effective amount of lycoramine.
Dependencies are inferred from the claim text.